Camelia Davtyan, MD, FACP Clinical Professor of Medicine Director of Women s Health UCLA Comprehensive Health Program
|
|
- Bethany Pearson
- 5 years ago
- Views:
Transcription
1
2 Camelia Davtyan, MD, FACP Clinical Professor of Medicine Director of Women s Health UCLA Comprehensive Health Program A B C D USPSTF recommends the service. There is high certainty that Offer or provide this service. the net benefit is substantial. USPSTF recommends the service. There is high certainty that the Offer or provide this service. net benefit is moderate, or moderate certainty that the net benefit is moderate/substantial. USPSTF recommends selectively offering or providing this service Offer or provide this service for to individual patients based on professional judgment/patient selected patients depending on preferences. There is at least moderate certainty that the net individual circumstances. benefit is small. USPSTF recommends against the service. There is moderate or Discourage the use of this service. high certainty that the service has no net benefit or that the harms outweigh the benefits. I Statement USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms. Evidence is lacking, of poor quality, or conflicting, and the balance of benefits and harms cannot be determined. If the service is offered, patients should understand the uncertainty about the balance of benefits and harms. High Moderate Low The available evidence includes consistent results from well-designed, well-conducted studies in representative primary care populations. These studies assess the effects of the preventive service on health outcomes. This conclusion is unlikely to be affected by the results of future studies. The available evidence is sufficient to determine the effects of the preventive service on health outcomes, but confidence in the estimate is constrained by such factors as: The number, size, or quality of individual studies. Inconsistency of findings across individual studies. Limited generalizability of findings to routine primary care practice. Lack of coherence in the chain of evidence. As more information becomes available, the magnitude or direction of the observed effect could change, and this change may be large enough to alter the conclusion. The available evidence is insufficient to assess effects on health outcomes. Evidence is insufficient because of: The limited number or size of studies. Important flaws in study design or methods. Inconsistency of findings across individual studies. Gaps in the chain of evidence. Findings not generalizable to routine primary care practice. Lack of information on important health outcomes. More information may allow estimation of effects on health outcomes. USPSTF Ann Intern Med 2012 Jun 19;156(12): ACOG Obstetrics & Gynecology, Volume 127(1), January 2016: American Cancer Society/American Society for Colposcopy and Cervical Pathology/American Society for Clinical Pathology (ACS/ASCCP/ASCP) CA Cancer J Clin 2012 May;62(3): Women ages : cytology every 3 provides a reasonable balance between benefits and harms Population Women yo Women yo Women < 21 Women after removal Women >65 with of the cervix (no adequate prior history of high-grade Women < 30 screening and pre-cancer or not at high risk cervical cancer) Cytology more often than every 3 confers little additional benefit HPV testing+ cytology (co-testing) every 5 in women ages offers a comparable balance of benefits and harms and can be done if women prefer to extend the screening interval cytology every 3 Recommendation cytology (Pap smear) every 3. Grade: A co-testing (cytology/hpv testing) every 5. Grade: A Do not screen. Do not screen. Do not screen. Do not screen with HPV testing (alone or with cytology) Screening earlier than age 21 regardless of sexual history, leads to more harms than benefits Clinicians and patients should base the decision to end screening on whether the patient meets the criteria for adequate prior testing and appropriate followup
3 Recommendations based on good and consistent scientific evidence (Level A): Screening should begin at age 21 (exception: women who are infected with HIV) Women aged 21 29: cervical cytology every 3 co-testing should not be performed (most will clear the HPV infection within 8-24 months ) annual screening should not be performed Women aged : co-testing with cytology and HPV testing every 5 is preferred cytology every 3 is acceptable (liquid-based and conventional methods both OK) annual screening should not be performed Women older than 65 : stop screening if adequate negative prior screening results and no history of CIN 2 or higher (3 consecutive negative cytology results or 2 consecutive negative co-test results within the previous 10, with the most recent test within the past 5 ) Women who had hysterectomy with removal of the cervix and have never had CIN 2 or higher, cytology screening and HPV testing should not be done Women with any of the following risk factors may require more frequent cervical cancer screening Women who are infected with HIV Women who are immunocompromised (e.g. organ transplants) Women who were exposed to diethylstilbestrol in utero Women previously treated for CIN 2, CIN 3, or cancer Recommendations based on limited and inconsistent scientific evidence (Level B) Women with a history of CIN 2, CIN 3, or adenocarcinoma in situ: continue screening for 20 after spontaneous regression/appropriate management of CIN 2, CIN 3, or adenocarcinoma in situ, even if past age 65 Women who had a total hysterectomy and have a history of cervical cancer or CIN 2 or higher in the past 20 : cytology alone every 3 for 20 after the initial treatment Women 25 and older: FDA-approved primary HPV screening test can be an alternative to cytology ASCUS positive cytology and negative HPV: repeat co-testing in 3 Cytology-negative and HPV-positive co-test in women >30 old: two options 1. Repeat co-testing in 12 months. If ASCUS or higher, or HPV positive, refer for colposcopy. Otherwise, co-test in 3 2. Immediate HPV genotype-specific testing for HPV-16 and HPV-18: positive test result: refer for colposcopy negative test results: repeat co-testing in 12 months Recommendation is based primarily on consensus and expert opinion (Level C) Women who have received the HPV vaccine should be screened according to the same guidelines as women who have not been vaccinated Professional Organization Age to initiate screening Screening interval ACS Age 21-29: cytology alone every 3 Age 30-65: cytology alone every 3 or cytology +HPV every 5 USPSTF Age 21-29: cytology alone every 3 Age 30-65: cytology alone every 3 or cytology +HPV every 5 ACOG Age 21-29: cytology alone every 3 Age 30-65:cytology alone every 3 or cytology+hpv every 5 Age to discontinue screening 65 if no recent abnormal Pap smears and no risk factors 65 if no recent abnormal Pap smears and no risk factors 65 if > 3 consecutive normal Pap smears or >2 consecutive normal Pap+HPV within 10 (most recent within 5 ) and no risk factors Risk factors: history of DES exposure, HIV positive, immunocompromise, previous treatment of a high-grade precancerous lesion or cervical cancer. Screening pelvic examination in adult women: A clinical practice guideline from the American College of Physicians Ann Intern Med 2014 Jul 1;161(1): ACP recommends against performing screening pelvic examination in asymptomatic, nonpregnant, adult women (strong recommendation, moderate-quality evidence) Indirect evidence that screening pelvic examination does not reduce mortality/morbidity in asymptomatic adult women No studies assessed the benefit of pelvic examination for other gynecologic conditions (asymptomatic pelvic inflammatory disease, benign conditions, or gynecologic cancer other than cervical or ovarian cancer) Low-quality evidence of harms related to screening pelvic examination (fear, anxiety, embarrassment, discomfort) Cervical cancer screening examination should be limited to visual inspection of the cervix and cervical swabs and should not entail a full pelvic examination. ACOG: Screening pelvic examination in adult women Committee on Gynecologic Practice, No. 534, August 2012 (Reaffirmed 2014) Annual pelvic examination of patients 21 of age or older is recommended Pelvic Examination: 1) inspection of the external genitalia, urethral meatus, vaginal introitus, and perianal region 2) speculum examination of the vagina and cervix 3) bimanual examination of the uterus, cervix, and adnexa; when indicated rectovaginal examination should be performed No evidence supports or refutes the annual pelvic examination (speculum and bimanual examination) for the asymptomatic, low-risk patient The decision whether or not to perform a complete pelvic examination for the asymptomatic patient should be a shared decision after a discussion between the patient and her health care provider.
4 At the time of menopause, all women should be told about the risks and symptoms of endometrial cancer Women should report any unexpected vaginal bleeding or spotting to their doctors Ovarian cancer is the leading cause of death from gynecologic malignancy in the US 22,000 new cases of ovarian cancer annually 14,000 cancer related deaths annually Population Recommendation Risk Assessment Asymptomatic women without known genetic mutations that increase risk for ovarian cancer Do not screen for ovarian cancer. Women with BRCA1 and BRCA2 genetic mutations, Lynch syndrome (hereditary nonpolyposis colon cancer), or a family history of ovarian cancer are at increased risk for ovarian cancer. Women with an increased-risk family history should have genetic counseling/evaluation: 2 or more first- or second-degree relatives with a history of ovarian cancer or a combination of breast and ovarian cancer women of Ashkenazi Jewish descent: 1 first-degree relative or 2 second-degree relatives on the same side of the family with breast or ovarian cancer. Screening Tests Transvaginal ultrasonography and serum cancer antigen (CA) 125 Balance of Benefits Annual screening with transvaginal ultrasonography and serum CA-125 testing in women does not and Harms decrease ovarian cancer mortality. Screening for ovarian cancer can lead to important harms, including major surgical interventions in women who do not have cancer. Harms of screening for ovarian cancer outweigh the benefits. SGO and NCCN (National Comprehensive Cancer Network): screen high risk women every 6 months with CA 125 and TVUS beginning at age or 5 10 earlier than the age of affected family member ACOG and NCI (National Cancer Institute): no evidence that screening improves survival in high risk women USPSTF: Ann Intern Med Feb 18;160(4): primary care providers should screen women who have a family history of breast, ovarian, tubal, or peritoneal cancer using a familial risk tool (Ontario Family Health Assessment Tool, Manchester Scoring System, Referral Screening Tool, Pedigree Assessment Tool, FHS-7, etc.) If positive screening result, refer for genetic counseling, with further BRCA testing if warranted. Women without a family history associated with an increased risk for mutations should not receive routine genetic counseling or BRCA testing Screen women whose family history may be associated with an Do not recommend genetic counseling or BRCA testing to increased risk for BRCA mutations and refer for genetic women whose family history is not associated with an counseling and BRCA testing (if indicated after counseling) increased risk for BRCA mutations GRADE D GRADE B High risk breast cancer diagnosis before age 50 bilateral breast cancer family history of breast and ovarian cancer or presence of breast cancer in 1 male family member multiple cases of breast cancer in the family ACOG: genetic risk assessment of women with >20%-25% risk for an inherited predisposition to breast and ovarian cancer ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome. Obstet Gynecol Apr. 113 (4): or more family member with 2 primary types of BRCA-related cancer Ashkenazi Jewish ethnicity
5 Screening Tests Intervention Balance of Benefits and Harms Genetic risk assessment and BRCA mutation testing are generally multistep processes involving identification of women who may be at increased risk for potentially harmful mutations, followed by genetic counseling by suitably trained health care providers and genetic testing of selected high-risk women when indicated Tests for BRCA mutations are highly sensitive and specific for known mutations, but interpretation of results is complex and generally requires posttest counseling earlier, more frequent, or intensive cancer screening risk-reducing medications (e.g., tamoxifen or raloxifene) risk-reducing surgery (e.g., mastectomy or salpingo-oophorectomy) In women whose family history is associated with In women whose family history is not an increased risk for potentially harmful BRCA associated with an increased risk for mutations, the net benefit of genetic testing and potentially harmful BRCA mutations, the early intervention is moderate. net benefit of genetic testing and early intervention ranges from minimal to potentially harmful. Genetic testing should be offered if: An individual has a personal or family history suggestive of an inherited cancer syndrome The genetic test can be adequately interpreted Testing will influence medical management of the patient or other relatives The potential benefits of testing outweigh the potential risks. Second-leading cause of cancer death among women in the United States Population Women aged Women aged Women aged 75 Recommendation Individualize decision to begin biennial screening according to the patient's circumstances and values. Grade: C Screen every 2. Grade: B No recommendation. Grade: I (Insufficient Evidence) Most frequently diagnosed among women aged In 2015 : 232, 000 women were diagnosed with the disease 40, 000 women died of BC (median age of death=68 ) Risk Assessment Screening Tests This recommendation applies to women aged 40 who are not at increased risk by virtue of a known genetic mutation or history of chest radiation. Increasing age is the most important risk factor for most women. Standardization of film mammography has led to improved quality. Timing of Screening Benefits of Benefits and Harms Rationale for No Recommendation (I Statement) Evidence indicates that biennial screening is optimal. A biennial schedule preserves most of the benefit of annual screening and cuts the harms nearly in half. A longer interval may reduce the benefit. There is convincing evidence that screening with film mammography reduces breast cancer mortality, with a greater absolute reduction for women aged 50 to 74 than for younger women. Harms of screening include psychological harms, additional medical visits, imaging, and biopsies in women without cancer, inconvenience due to false-positive screening results, harms of unnecessary treatment, and radiation exposure. False-positive results are a greater concern for younger women; treatment of cancer that would not become clinically apparent during a woman's life (overdiagnosis) is an increasing problem as women age. Among women 75 or older, evidence of benefit is lacking These recommendations apply to asymptomatic women aged >40 No history of breast cancer/high risk breast lesion No high risk for breast cancer because of a genetic mutation (BRCA1 or BRCA2 or other familial breast cancer syndrome) No history of chest radiation at a young age) DBT (digital breast tomosynthesis) as primary screening: insufficient evidence (I recommendation) Adding other methods (ultrasound, MRI) in women with dense breasts and negative mammogram: insufficient evidence (I recommendation) false positive results are common and more frequent in younger women, women with dense breasts (use of DBT may reduce false positives) Biennial screening avoids 7 BC deaths Annual screening avoids 10 BC deaths and yields 11 more overdiagnoses per 1,000 women screened
6 Women age 40 49: "C" recommendation is not a recommendation against mammography screening; it signifies moderate certainty of a small net benefit for screening The decision to screen should be an individual one, made after a woman weighs the potential benefit against the possible harms Women with a first degree relative (parent, child, or sibling) with breast cancer may potentially benefit more than average risk women False positives and recommendations for additional imaging (125/1,000) are highest in women (Ann Intern Med 2016; 164: ) Advances in systemic therapy (Ann Intern Med 2016; 164: ) have not reduced the relative benefits of screening have reduced the absolute benefits because of their positive effect on survival How hard should we try to prevent one death from breast cancer? RR for BC mortality per 10,000 women screened over for age 39 49; 3 deaths prevented 0.86 for age 50 59; 8 deaths prevented 0.67 for age 60 69; 21 deaths prevented 0.8 for age 70 74; 13 deaths prevented Radiation induced breast cancer incidence and mortality from digital mammography screening Ann Intern Med 2016; 164: Annual screening of 100,000 women aged induces 125 breast cancer cases leading to 16 deaths averts 968 breast cancer cases by early detection Biennial screening started at age 50 reduced the risk of radiation induced cancer 5 folds Women who need more views (large breasts, implants) have a higher risk of radiation induced cancer Recommendations based on limited and inconsistent scientific evidence (Level B): women aged 40 and older should be offered screening mammography annually Recommendations based primarily on consensus and expert opinion (Level C): Clinical breast examination: women aged > 40 annually women aged every 1 3. Breast self awareness should be encouraged and can include breast self examination. Women should report any changes in their breasts to their health care providers. Educate women on predictive value of screening mammography potential for false positive results and false negative results potential for additional imaging or biopsies that may be recommended Women with lifetime risk of breast cancer of 20% or greater, based on risk models that rely on family history (such as BRCAPRO, BODACEA, or Claus), but who are either untested or test negative for BRCA gene mutations, can be offered enhanced screening. MRI is not recommended for screening average risk women at average risk Women who test positive for BRCA1 and BRCA2 mutations: Recommend enhanced screening Discuss risk reduction methods Women ages 40 to 44 should have the choice to start annual breast cancer screening with mammograms if they wish to do so Women age 45 to 54 should get annual mammograms Women 55 and older should get mammograms every 2, or have the choice to continue yearly screening When to stop screening: Screening should continue as long as a woman is in good health and is expected to live >10 more All women should be familiar with the benefits, limitations, and potential harms linked to breast cancer screening. They should know how their breasts normally look and feel and report any breast changes to a health care provider Annual MRI and a mammogram starting at age 30 and continued for as long as a woman is in good health (evidence is limited about the best age to start screening shared decision making between patients and their health care providers) Lifetime risk of breast cancer of >20% 25% based on risk assessment tools rely on family history (such as the Claus model) Known BRCA1 or BRCA2 gene mutation First degree relative (parent, brother, sister, or child) with a BRCA1 or BRCA2 gene mutation, and have not had genetic testing History of radiation therapy to the chest between the ages of Diagnosis of Li Fraumeni syndrome, Cowden syndrome, Bannayan Riley Ruvalcaba syndrome, or have first degree relatives with one of these syndromes Some women (because of family history, a genetic tendency, or other factors) should be screened with annual MRIs along with mammograms.
7 There s not enough evidence to make a recommendation for or against yearly MRI screening for women who: Have a moderately increased risk of breast cancer (lifetime risk of 15% to 20%) Have dense breasts ( extremely or heterogeneously dense) on mammogram Gail model bases its risk estimates on certain personal risk factors (current age, age at first menstrual period and history of prior breast biopsies) along with any history of breast cancer in first degree relatives Claus model estimates risk based only on family history of breast cancer in both first and second degree relatives Risk assessment tools (like the Gail model) that are not based mainly on family history are not appropriate to use with the ACS guidelines to decide if a woman should have MRI screening Women at average risk: Yearly screening from age 40: until life expectancy is <5 7 or if abnormal results of screening would not be acted upon (age or comorbid conditions) Women at increased risk: Women with BRCA1 or BRCA2 mutations or women who are untested but have firstdegree relatives (mothers, sisters, or daughters) who have a BRCA mutation: Yearly screening starting by age 30 (but not before age 25) Women with 20% lifetime risk for breast cancer on the basis of family history (both maternal and paternal) and women with mothers or sisters with pre menopausal breast cancer : Yearly starting by age 30 (but not before age 25), or 10 earlier than the age of diagnosis of the youngest affected relative Women with histories of mantle radiation (usually for Hodgkin's disease) between the ages of 10 30: Yearly starting 8 after the radiation therapy, but not before age 25 Women with biopsy proven lobular neoplasia (lobular carcinoma in situ and atypical lobular hyperplasia), atypical ductal hyperplasia (ADH), ductal carcinoma in situ (DCIS), invasive breast cancer or ovarian cancer: Yearly from time of diagnosis
Updates In Cancer Screening: Navigating a Changing Landscape
Updates In Cancer Screening: Navigating a Changing Landscape Niharika Dixit, MD I have no conflict of interest. 1 Why Should You Care Trends in Cancer Incidence by Site United States. Siegal Et al: CA
More informationI have no financial interests in any product I will discuss today.
How Should We Approach Cervical Cancer Screening and Routine Pelvic Examinations in 2019? Michael Policar, MD, MPH Professor Emeritus Department of Obstetrics, Gynecology and Reproductive Sciences University
More informationUntangling the Confusion: Multiple Breast Cancer Screening Guidelines and the Ones We Should Follow
Untangling the Confusion: Multiple Breast Cancer Screening Guidelines and the Ones We Should Follow Debra A. Walz, RN, MS, AOCNP, WHNP-BC, RNFA Advanced Oncology & Women s Health Nurse Practitioner Oneida
More informationObjectives. I have no financial interests in any product I will discuss today. Cervical Cancer Screening Guidelines: Updates and Controversies
Cervical Cancer Screening Guidelines: Updates and Controversies I have no financial interests in any product I will discuss today. Jody Steinauer, MD, MAS University of California, San Francisco Objectives
More informationI have no financial interests in any product I will discuss today.
Cervical Cancer Screening Update and Implications for Annual Exams George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics
More informationI have no financial interests in any product I will discuss today.
Cervical Cancer Prevention: 2012 and Beyond George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics University of California,
More informationI have no financial interests in any product I will discuss today.
Cervical Cancer Screening Update and Implications for Annual Exams George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics
More informationTHE MODERN GYNECOLOGIC EXAMINATION & SCREENING FOR GYNECOLOGIC MALIGNANCIES
THE MODERN GYNECOLOGIC EXAMINATION & SCREENING FOR GYNECOLOGIC MALIGNANCIES Denise Uyar, MD Associate Professor OB/GYN Chief Gynecologic Oncology Medical College of Wisconsin April 12, 2019 NO DISCLOSURES
More informationNATIONAL GUIDELINE CLEARINGHOUSE (NGC) GUIDELINE SYNTHESIS SCREENING FOR BREAST CANCER
NATIONAL GUIDELINE CLEARINGHOUSE (NGC) GUIDELINE SYNTHESIS SCREENING FOR BREAST CANCER Guidelines 1. American Cancer Society (ACS). (1) ACS guidelines for breast cancer screening: update 2003. (2) American
More information10/25/2011 OBJECTIVES Cancer Screening in the United States, 2011 A Review of Current American Cancer Society Guidelines and Issues in Cancer Screenin
OBJECTIVES Cancer Screening in the United States, 2011 A Review of Current American Cancer Society Guidelines and Issues in Cancer Screening Kathy Gray, DNP, CRNP, FNP-BC Cancer Screenings and Guidelines
More informationCLINICAL GUIDELINES. Screening Mammography Guidelines
CLINICAL GUIDELINES Screening Mammography Guidelines Paula George, M.D. and C. Todd Cunningham, M.D., Karen F. Goodhope, M.D., Valerie C. Reichert, M.D. Hayley Sheldon, M.D., Michelle Walters, D.O. 2/17/2016
More informationBreast Cancer Imaging
Breast Cancer Imaging I. Policy University Health Alliance (UHA) will cover breast imaging when such services meet the medical criteria guidelines (subject to limitations and exclusions) indicated below.
More informationCervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines. June 2013
Cervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines General Principles: Since its introduction in 1943, Papanicolaou (Pap) smear is widely
More informationBreast Cancer Risk Assessment: Genetics, Risk Models, and Screening. Amie Hass, MSN, ARNP, FNP-BC Hall-Perrine Cancer Center
Breast Cancer Risk Assessment: Genetics, Risk Models, and Screening Amie Hass, MSN, ARNP, FNP-BC Hall-Perrine Cancer Center Disclosure- I DO NOT HAVE any relevant financial interest with any entity producing,
More informationCANCER SCREENING. Er Chaozer Department of General Medicine, Tan Tock Seng Hospital
CANCER SCREENING Er Chaozer Department of General Medicine, Tan Tock Seng Hospital Introduction Screening average risk patients Benefits and harms from screening Early cancer detection early treatment
More informationCVIM s Cancer Screening Practices
12-13-17 Professional Practice Minutes CVIM s Cancer Screening Practices At CVIM, preventative health care is very important! In these minutes you will find a review of our recommendations for cancer screening
More informationPap Smears Pelvic Examinations Well Woman Examinations. When should you have them performed???
Pap Smears Pelvic Examinations Well Woman Examinations. When should you have them performed??? Arlene Evans-DeBeverly, PA-C Copyright 2012 There are always ongoing changes in gynecology, including the
More informationMammography and Other Screening Tests. for Breast Problems
301.681.3400 OBGYNCWC.COM Mammography and Other Screening Tests What is a screening test? for Breast Problems A screening test is used to find diseases, such as cancer, in people who do not have signs
More informationBreast Cancer Screening Clinical Practice Guideline. Kaiser Permanente National Breast Cancer Screening Guideline Development Team
NATIONAL CLINICAL PRACTICE GUIDELINE Breast Cancer Screening Clinical Practice Guideline Kaiser Permanente National Breast Cancer Screening Guideline Development Team This guideline is informational only.
More informationMelissa Hartman, DO Women s Health Orlando VA Medical Center
Melissa Hartman, DO Women s Health Orlando VA Medical Center Most common non-skin cancer and Second deadliest cancer in women Majority are diagnosed by abnormal screening study An approach to breast cancer
More informationDisclosures. Learning objectives. George F. Sawaya, MD. I have nothing to disclose.
Well Woman Visits in 2018: How Should We Approach Cervical Cancer Screening and Routine Pelvic Examinations? George F. Sawaya, MD Disclosures I have nothing to disclose. Professor, Obstetrics, Gynecology
More informationGuidelines for Breast, Cervical and Colorectal Cancer Screening
Guidelines for Breast, Cervical and Colorectal Cancer Screening Your recommendation counts. Talk to your patients about screening for cancer. CancerCare Manitoba provides organized, population-based screening
More informationMenopause and Cancer risk; What to do overcome the risks? Fatih DURMUŞOĞLU,M.D
Menopause and Cancer risk; What to do overcome the risks? Fatih DURMUŞOĞLU,M.D Menopause and Cancer How does menopause affect a woman s cancer risk? Ø Menopause does not cause cancer.but risk of developing
More informationBreast Imaging! Ravi Adhikary, MD!
Breast Imaging! Ravi Adhikary, MD! ACS Estimated Cancers Statistics 2014! Breast! New Cases in Women! 232,670 (+67,570 in situ)! Deaths in Women! 40,000! Colon! 48,380! 24,040! Cervical! 12,360! 4,020!
More informationObjectives. Background. Background. Background. Background 9/26/16. Update on Cervical and HPV Screening Guidelines: To pap or not to pap?
Update on Cervical and HPV Screening Guidelines: To pap or not to pap? Marina Delazari Miller MD Clinical Assistant Professor Department of Obstetrics & Gynecology University of Iowa Hospitals and Clinics
More informationAssessing Your Patient s Breast Cancer Risk: Is Genetic Testing Necessary?
May 16, 2016 Assessing Your Patient s Breast Cancer Risk: Is Genetic Testing Necessary? Presenter: Emily Kuchinsky, MS, CGC 1 Experiences with Genetic Testing Adverse Events in Cancer Genetic Testing:
More informationPreventive Care Guideline for Asymptomatic Low Risk Adults Age 18 through 64
Preventive Care Guideline for Asymptomatic Low Risk Adults Age 18 through 64 1. BMI - Documented in patients medical record on an annual basis. Screen for obesity and offer intensive counseling and behavioral
More informationRisk Assessment, Genetics, and Prevention
Risk Assessment, Genetics, and Prevention Katherine D. Crew, MD MS Director, Clinical Breast Cancer Prevention Program Columbia University Medical Center 1 Outline Breast cancer risk factors Hereditary
More informationDysplasia: layer of the cervical CIN. Intraepithelial Neoplasia. p16 immunostaining. 1, Cervical. Higher-risk, requires CIN.
CLINICAL PRACTICE GUIDELINE Guideline Number: DHMP_DHMC_PG1015 Guideline Subject: Routine Cervical Cancer Screening Effective Date: 9/2018 Revision Date: 9/2019 Pages: 2 of 2 Quality Management Committee
More informationThe U.S. Preventive Services Task Force (USPSTF) CLINICAL GUIDELINE
Annals of Internal Medicine CLINICAL GUIDELINE Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement Albert L. Siu, MD, MSPH, on behalf of the U.S. Preventive Services
More informationSamuel B. Wolf, D.O., F.A.C.O.G. Emerald Coast Obstetrics and Gynecology Panama City Florida
Making sense of the new Pap smear screening guidelines. Samuel B. Wolf, D.O., F.A.C.O.G. Emerald Coast Obstetrics and Gynecology Panama City Florida Case 17 year old G1P0010 with first sexual encounter
More informationScreening Mammograms: Questions and Answers
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Screening Mammograms:
More informationAn Update on Cervical Cancer Screening Recommendations and on the DOH BCC Program
An Update on Cervical Cancer Screening Recommendations and on the DOH BCC Program Susan Baum, MD, MPH NM Nurse Practitioner Council Annual Conference April 20, 2012 I have no commercial relationships related
More informationEvidence-based Cancer Screening & Surveillance
Oncology for Scientists Spring 2014 Evidence-based Cancer Screening & Surveillance Martin C. Mahoney, MD, PhD, FAAFP Departments of Medicine & Health Behavior /Oncology_Feb 2014.ppt 1 Objectives: Principles
More informationCancer Screening I have no conflicts of interest. Principles of screening. Cancer in the World Page 1. Letting Evidence Be Our Guide
Cancer Screening 2012 Letting Evidence Be Our Guide Jeffrey A. Tice, MD Division of General Internal Medicine University of California, San Francisco I have no conflicts of interest Principles of screening
More informationGuidelines for the Early Detection of Cancer
Guidelines for the Early Detection of Cancer The American Cancer Society recommends these cancer screening guidelines for most adults. Screening tests are used to find cancer before a person has any symptoms.
More informationNorth American Menopause Society (NAMS)
North American Menopause Society (NAMS) 2012 Hormone Therapy Position Statement Cynthia B. Evans, MD Assistant Professor-Clinical Department of Obstetrics and Gynecology The Ohio State University College
More informationCANCER SCREENING USPSTF AND BEYOND. DeAnn Cummings, MD March 9, 2019
CANCER SCREENING USPSTF AND BEYOND DeAnn Cummings, MD March 9, 2019 OBJECTIVES Review and discuss cancer screening guidelines for: Colorectal CA Prostate CA Breast CA Ovarian CA Secondary prevention, NOT
More informationWellness Along the Cancer Journey: Healthy Habits and Cancer Screening Revised October 2015 Chapter 7: Cancer Screening and Early Detection of Cancer
Wellness Along the Cancer Journey: Healthy Habits and Cancer Screening Revised October 2015 Chapter 7: Cancer Screening and Early Detection of Cancer Healthy Habits and Cancer Screening Rev 10.20.15 Page
More informationScreening Mammography: The Controversy, Risk Assessment and Individualized Screening recommendations. Jonathan T. Sims MD, MBA
Screening Mammography: The Controversy, Risk Assessment and Individualized Screening recommendations. Jonathan T. Sims MD, MBA I have no relevant Financial Disclosures Agenda Discuss the recent studies
More informationCANCER SCREENING USPSTF AND BEYOND. DeAnn Cummings, MD March 3, 2018
CANCER SCREENING USPSTF AND BEYOND DeAnn Cummings, MD March 3, 2018 OBJECTIVES Review and discuss cancer screening guidelines for: Colorectal CA Prostate CA Breast CA Ovarian CA Secondary prevention, NOT
More informationSo, Who are the appropriate individuals that should consider genetic counseling and genetic testing?
Hello, I m Banu Arun, Professor of Breast Medical Oncology and Co-Director of Clinical Cancer Genetics at the University of Texas MD Anderson Cancer Center. Today I will be discussing with you Hereditary
More informationWomen s Health: Breast Cancer Screening. K. Rast, MD and E. McNany, MD
Women s Health: Breast Cancer Screening K. Rast, MD and E. McNany, MD 2013 2017 Update: Who? How? When? Cases and Practice Questions Question 1 A 40 year old female comes to your office for a well woman
More informationBreast Cancer Screening in Women at Higher-Than-Average Risk: Recommendations From the ACR
ORIGINAL ARTICLE CLINICAL PRACTICE MANAGEMENT Breast Cancer Screening in Women at Higher-Than-Average Risk: Recommendations From the ACR Debra L. Monticciolo, MD a, Mary S. Newell, MD b, Linda Moy, MD
More informationEvaluations & CE Credits
Evaluations & CE Credits Nursing Contact Hours, CME and CHES credits are available. Please visit www.phlive.org to fill out your evaluation and complete the post-test. 1 Breast Density and Breast Cancer
More informationRecommendation Summary U S. Prevention Statement Task Force for HPV (USPSTF)
Recommendation Summary U S. Prevention Statement Task Force for HPV (USPSTF) Population Recommendation Grade (What's This?) Women ages 21 to 65 years The USPSTF recommends screening for cervical cancer
More informationBreast Cancer Screening
Breast Cancer Screening Claire Frost, MD R3 Talks 1 Objective 1. Understand risks and benefits of screening by reviewing current literature 2. Evaluate major society recommendations on breast cancer screening
More informationNicolaus Copernicus University in Torun Medical College in Bydgoszcz Family Doctor Department CANCER PREVENTION IN GENERAL PRACTICE
Nicolaus Copernicus University in Torun Medical College in Bydgoszcz Family Doctor Department CANCER PREVENTION IN GENERAL PRACTICE A key mission for family medicine is preserving health and maximizing
More informationScreening Mammography Policy and Politics. Kevin L. Piggott, MD, MPH August 29, 2015
Screening Mammography Policy and Politics Kevin L. Piggott, MD, MPH August 29, 2015 Objectives 1. To review the current recommendations for screening mammography by various national groups 2. To provide
More informationBreast Cancer Screening: Changing Philosophies in Educating Women and Teens
Breast Cancer Screening: Changing Philosophies in Educating Women and Teens Courtney Benedict CNM MSN Disclosures Merck Nexplanon trainer Session Objectives Explain the rationale for initiation and frequency
More informationBreast Cancer Screening and Diagnosis
Breast Cancer Screening and Diagnosis Priya Thomas, MD Assistant Professor Clinical Cancer Prevention and Breast Medical Oncology University of Texas MD Anderson Cancer Center Disclosures Dr. Thomas has
More informationEvaluation & Management of PowerPoint Cover Title. the High Risk Population. High Risk Clinic
Evaluation & Management of PowerPoint Cover Title the High Risk Population High Risk Clinic Subtitle Joanna Would Springman, Go Here PA-C Assessment Genetics Known genetic mutation Family history with
More informationBreast Cancer Risk Assessment and Prevention
Breast Cancer Risk Assessment and Prevention Katherine B. Lee, MD, FACP October 4, 2017 STATISTICS More than 252,000 cases of breast cancer will be diagnosed this year alone. About 40,000 women will die
More informationMaking Sense of Cervical Cancer Screening
Making Sense of Cervical Cancer Screening New Guidelines published November 2012 Tammie Koehler DO, FACOG The incidence of cervical cancer in the US has decreased more than 50% in the past 30 years because
More informationBreast Cancer Risk Factors 8/3/2014
Breast Cancer Screening: Changing Philosophies in Educating Women and Teens Courtney Benedict CNM MSN Session Objectives Explain the rationale for initiation and frequency of clinical breast exams to clients
More informationClinical guideline Published: 25 June 2013 nice.org.uk/guidance/cg164
Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer Clinical guideline Published: 25 June 2013 nice.org.uk/guidance/cg164
More informationPrimary Care Approach to Genetic Cancer Syndromes
Primary Care Approach to Genetic Cancer Syndromes Jason M. Goldman, MD, FACP FAU School of Medicine Syndromes Hereditary Breast and Ovarian Cancer (HBOC) Hereditary Nonpolyposis Colorectal Cancer (HNPCC)
More informationOBJECTIVES 8/25/2017. An attempt to organize the chaos
High Risk for Breast Cancer and Genetics: Who? What? Where? When? An attempt to organize the chaos Presented at Winds of Change Conference November 3, 2017 by Carol Hager, MSN, CRNP and Allison Haener,
More informationCervical Cancer Screening. David Quinlan December 2013
Cervical Cancer Screening David Quinlan December 2013 Cervix Cervical Cancer Screening Modest variation provincially WHO and UK begin at 25 stop at 60 Finland begin at 30 stop at 60 Rationale for
More informationProgram Guidelines Clinical Guidelines Patient Enrollment Resource Documents Eligibility Guidelines... 2
BREAST AND CERVICAL CANCER TABLE OF CONTENTS Program Guidelines... 1 Clinical Guidelines... 1 Patient Enrollment... 1 Resource Documents... 1 Eligibility Guidelines... 2 Breast Screening Guidelines and
More informationHigh Risk or High Reward: Breast Cancer Prevention and Screening in Primary Care: New Challenges and Opportunities
High Risk or High Reward: Breast Cancer Prevention and Screening in Primary Care: New Challenges and Opportunities Section 1 Jamie Stern, MD, MPH: Mammography in the 40s and 50s: the Data and the Controversy
More informationCervical Cancer Screening Update. Melissa Hartman, DO Women s Health
Cervical Cancer Screening Update Melissa Hartman, DO Women s Health Previous Cervical Cancer Screening Organization Recommendation ACS (2011) ACP (2008) NCI (2003) Age 21 or 3 years after first intercourse
More informationHBOC Syndrome A review of BRCA 1/2 testing, Cancer Risk Assessment, Counseling and Beyond.
HBOC Syndrome A review of BRCA 1/2 testing, Cancer Risk Assessment, Counseling and Beyond. Conni Murphy, ARNP Cancer Risk Assessment and Genetics Program Jupiter Medical Center Learning Objectives Identify
More informationPreventive Care Guideline for Asymptomatic Elderly Patients Age 65 and Over
Preventive Care Guideline for Asymptomatic Elderly Patients Age 65 and Over 1. BMI - Documented in patients medical record on an annual basis up to age 74. Screen for obesity and offer counseling to encourage
More informationThis information explains the advice about familial breast cancer (breast cancer in the family) that is set out in NICE guideline CG164.
Familial breast cancer (breast cancer in the family) Information for the public Published: 1 June 2013 nice.org.uk About this information NICE guidelines provide advice on the care and support that should
More informationShared Decision Making in Breast and Prostate Cancer Screening. An Update and a Patient-Centered Approach. Sharon K. Hull, MD, MPH July, 2017
Shared Decision Making in Breast and Prostate Cancer Screening An Update and a Patient-Centered Approach Sharon K. Hull, MD, MPH July, 2017 Overview Epidemiology of Breast and Prostate Cancer Controversies
More informationPage 1. Cancer Screening for Women I have no conflicts of interest. Overview. Breast, Colon, and Lung Cancer. Jeffrey A.
Cancer Screening for Women 2017 Breast, Colon, and Lung Cancer Jeffrey A. Tice, MD Professor of Medicine Division of General Internal Medicine University of California, San Francisco I have no conflicts
More informationHereditary Breast and Ovarian Cancer (HBOC) Information for individuals and families
Hereditary Breast and Ovarian Cancer (HBOC) Information for individuals and families What is Hereditary Breast and Ovarian Cancer (HBOC)? Hereditary Breast and Ovarian Cancer is a genetic condition which
More informationRisk Assessment and Risk Management
Risk Assessment and Risk Management Epworth Benign Breast Disease Symposium Dr Laura Chin-Lenn 12 November 2016 Why identify those at increased risk of breast cancer? Should I be worried? 1 Why identify
More informationScreening for Breast Cancer
Understanding Task Force Recommendations Screening for Breast Cancer U.S. Preventive Services Task Force (Task Force) has issued a final recommendation statement on Screening for Breast Cancer. se final
More informationHuman Papillomavirus (HPV) and Cervical Cancer Prevention
Human Papillomavirus (HPV) and Cervical Cancer Prevention MOA Autumn Convention November 3, 2017 David J Boes, DO, FACOOG (Dist.) Associate Professor, MSU-COM 1 Disclosures None relative to this presentation
More informationEnlightened Well Woman Care. Jennifer K. Phillips MD 1/22/2014
Enlightened Well Woman Care Jennifer K. Phillips MD 1/22/2014 Case 1 17 yr old young woman Never been pregnant Sexually active and interested in birth control Non-smoker What screening tests are important?
More informationIs It Time To Implement Ovarian Cancer Screening?
Is It Time To Implement Ovarian Cancer Screening? Prof Dr Samet Topuz Istanbul Medıcal Faculty Department Of Obstetrics and Gynecology ESGO Prevention in Gynaecological Malignancies September 08 2016 Antalya
More informationCancer Treatment Centers of America: Supercharge Your Knowledge: A Focus on Breast, Cervical and Prostate Screening Guidelines and Controversies
8 ACOFP 55th Annual Convention & Scientific Seminars Cancer Treatment Centers of America: Supercharge Your Knowledge: A Focus on Breast, Cervical and Prostate Screening Guidelines and Controversies Anthony
More informationContact Information. Permanent Address: Mailing Address (if different than above): Please check preferred method(s) of contact.
Contact Information Please fill out this form as completely as possible. You will not need to complete any additional medical health history forms on the day of your visit. Name: Date: Permanent Address:
More informationThe Guidelines Guide: Routine Adult Screening Created March 2009 by Alana Benjamin, MD Last updated: June 29 th, 2010
The Guidelines Guide: Routine Adult Screening Created March 2009 by Alana Benjamin, MD Last updated: June 29 th, 2010 Table of Contents Topic Page Introduction 2 Abbreviations 2 USPSTF Grades of Recommendations
More informationClinical Practice Guidelines June 2013
Clinical Practice Guidelines June 2013 General Principles: The Papanicolaou (Pap) smear is widely credited with reducing mortality from cervical cancer, and remains the single best method for the early
More information10/20/2015. Valerie Ballard, DNP Women s Health Nurse Practitioner
S.Storm - Dementia Valerie Ballard, DNP Women s Health Nurse Practitioner A WELL VISIT IS PART OF A JOURNEY TO WELLNESS AND HEALTH FOR OUR PATIENTS. As a provider, take the opportunity to listen, teach
More informationNon-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.
MRI OF THE BREAST Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationChapter 7 Section 2.1. Clinical Preventive Services - TRICARE Standard
Medicine Chapter 7 Section 2.1 Issue Date: April 19, 1983 Authority: 32 CFR 199.4(e)(28) and (f)(12), 10 USC 1079(a), Public Law 110-471, Section 711 1.0 CPT 1 PROCEDURE CODES 45300-45305, 45308-45315,
More informationPatient Information. Name: (Last) (First) (Middle) Address: (Street) (City) (State) (Zip) Home Phone: Cell Phone: address:
Patient Information Name: (Last) (First) (Middle) Address: (Street) (City) (State) (Zip) Home Phone: Cell Phone: Email address: Birth date: _ Age: Social Security.: When is the best time to contact you?
More informationGenetic Risk Evaluation and Testing Program
INSTRUCTIONS: Please complete this form to the best of your ability PRIOR to your appointment. Please remember to list ALL relatives, both living and deceased, regardless of if they have had cancer or
More informationBREAST AND CERVICAL CANCER CONTROL NAVIGATION PROGRAM MEDICAL PROTOCOL OCTOBER 2018
1 TABLE OF CONTENTS I. Introduction page 2 II. BCCCNP Clinical Services Provided to Eligible Clients - page 3 III. BCCCNP Age and Insurance Eligibility to Receive Breast and Cervical Cancer Screening and/or
More informationCervical Screening for Dysplasia and Cancer in Patients with HIV
Cervical Screening for Dysplasia and Cancer in Patients with HIV Adult Clinical Guideline from the New York State Department of Health AIDS Institute w w w.hivg uidelines.org Purpose of the Guideline Increase
More information2019 Adult Preventive Health Guidelines
1 2019 Adult Preventive Health Guidelines Important Note Health Net s Preventive Health Guidelines provide Health Net members and practitioners with recommendations for preventive care services for the
More informationCancer Genomics 101. BCCCP 2015 Annual Meeting
Cancer Genomics 101 BCCCP 2015 Annual Meeting Objectives Identify red flags in a person s personal and family medical history that indicate a potential inherited susceptibility to cancer Develop a systematic
More informationHereditary Breast and Ovarian Cancer Rebecca Sutphen, MD, FACMG
Hereditary Breast and Ovarian Cancer 2015 Rebecca Sutphen, MD, FACMG Among a consecutive series of 11,159 women requesting BRCA testing over one year, 3874 responded to a mailed survey. Most respondents
More information6 Week Course Agenda. Today s Agenda. Ovarian Cancer: Risk Factors. Winning the War 11/30/2016 on Women s Cancer Gynecologic Cancer Prevention
6 Week Course Agenda Winning the War 11/30/2016 on Women s Cancer Gynecologic Cancer Prevention Lee-may Chen, MD Director, Division of Gynecologic Oncology Professor Department of Obstetrics, Gynecology
More informationHereditary Cancer Risk Program
Hereditary Cancer Risk Program Family History and Risk Assessment Questionnaire Please answer questions to the best of your ability in order to help us establish your risk assessment. Write in unk (unknown)
More informationImproving the Identification of Underserved Women at High Risk for Breast Cancer and Increasing the use of Breast MRI Screening in this Population
Improving the Identification of Underserved Women at High Risk for Breast Cancer and Increasing the use of Breast MRI Screening in this Population Greenwood HI, Truong L, Price ER. UCSF Department or Radiology
More informationTissue Breast Density
Tissue Breast Density Reporting breast density within the letter to the patient is now mandated by VA law. Therefore, this website has been established by Peninsula Radiological Associates (PRA), the radiologists
More informationPreventive Health Guidelines
Preventive Health Guidelines Guide to Clinical Preventive Services Adult LifeWise has adopted the United States Preventive Services Task Force (USPSTF) Guide to Clinical Preventive Services. The guideline
More informationBreast Cancer Screening and High Risk
Breast Cancer Screening and High Risk Mary Freyvogel, DO Breast Surgeon Clinical Assistant Professor of Surgery University Hospitals Case Medical Center St. John Medical Center / Elyria Medical Center
More informationUpdate on Cervical Cancer Screening. Rahmouna Farez M.D. Assistant Professor, Medical College of Wisconsin 5/2/2014
Update on Cervical Cancer Screening Rahmouna Farez M.D. Assistant Professor, Medical College of Wisconsin 5/2/2014 Objectives Review the natural history of HPV as it relates to cervical cancer screening
More informationUpdate on Cervical Cancer Screening
Update on Cervical Cancer Screening Rahmouna Farez M.D. Assistant Professor, Medical College of Wisconsin 5/2/2014 Objectives Review the natural history of HPV as it relates to cervical cancer screening
More informationGuidelines in Breast Screening Mammography: Pros and Cons JOSLYN ALBRIGHT, MD SURGICAL ONCOLOGIST, ADVOCATE CHRIST MEDICAL CENTER OCTOBER 1, 2016
Guidelines in Breast Screening Mammography: Pros and Cons JOSLYN ALBRIGHT, MD SURGICAL ONCOLOGIST, ADVOCATE CHRIST MEDICAL CENTER OCTOBER 1, 2016 FACT Breast Cancer Screening Saves Lives Since 1990, screening
More informationScreening for Genes for Hereditary Breast and Ovarian Cancer in Jewish Women
Screening for Genes for Hereditary Breast and Ovarian Cancer in Jewish Women Background About 5% of women in Canada with breast cancer and about 12% of women with ovarian cancer, are born with an inherited
More informationProtect & Detect: What Women should Know about cancer. The American College of Obstetricians and Gynecologists
Protect & Detect: What Women should Know about cancer The American College of Obstetricians and Gynecologists A Message From ACOG President Kenneth L. Noller, MD Dr. Noller is the Louis E. Phaneuf professor
More informationSCREENING FOR OVARIAN CANCER DR MACİT ARVAS
SCREENING FOR OVARIAN CANCER DR MACİT ARVAS Ovarian cancer is the leading cause of death from gynecologic malignancy In 2008, ovarian cancer was the seventh common cancer in women worldwide There were
More informationGynecologic Cancers are many diseases. Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine. Speaker Disclosure:
Gynecologic Cancer Care in the Age of Precision Medicine Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine Lee-may Chen, MD Department of Obstetrics, Gynecology & Reproductive
More information